Jim Simons’s Allena Pharmaceuticals ALNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-17,200
| Closed | -$3K | – | 4569 |
|
|
2022
Q2 | $3K | Buy |
+17,200
| New | +$2.66K | ﹤0.01% | 4173 |
|
|
2021
Q4 | – | Sell |
-132,700
| Closed | -$120K | – | 4340 |
|
|
2021
Q3 | $120K | Sell |
132,700
-567,901
| -81% | -$556K | ﹤0.01% | 3294 |
|
|
2021
Q2 | $911K | Buy |
700,601
+214,671
| +44% | +$260K | ﹤0.01% | 2711 |
|
|
2021
Q1 | $675K | Buy |
485,930
+238,919
| +97% | +$398K | ﹤0.01% | 2789 |
|
|
2020
Q4 | $316K | Buy |
+247,011
| New | +$344K | ﹤0.01% | 3015 |
|
|
2020
Q3 | – | Sell |
-617,270
| Closed | -$975K | – | 3802 |
|
|
2020
Q2 | $975K | Buy |
617,270
+215,492
| +54% | +$362K | ﹤0.01% | 2552 |
|
|
2020
Q1 | $387K | Buy |
401,778
+160,078
| +66% | +$320K | ﹤0.01% | 2881 |
|
|
2019
Q4 | $660K | Buy |
241,700
+115,300
| +91% | +$379K | ﹤0.01% | 2796 |
|
|
2019
Q3 | $498K | Buy |
126,400
+50,200
| +66% | +$215K | ﹤0.01% | 2869 |
|
|
2019
Q2 | $310K | Buy |
76,200
+61,400
| +415% | +$335K | ﹤0.01% | 3165 |
|
|
2019
Q1 | $104K | Buy |
+14,800
| New | +$107K | ﹤0.01% | 3296 |
|
Other funds holding ALNA
Jim Simons's ALNA Position: Q3 2022 in Review
Jim Simons sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 17,200 shares — an estimated $3K sold.
Jim Simons first reported a position in ALNA in Q1 2019 and held it in 11 quarters. The position peaked at $975K in Q2 2020. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.
- Jim Simons reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Jim Simons sold 17,200 Allena Pharmaceuticals shares in Q3 2022, an estimated $3K.
- Jim Simons first reported a position in Allena Pharmaceuticals in Q1 2019 and held it in 11 quarters.
- Jim Simons's Allena Pharmaceuticals position peaked at $975K in Q2 2020.
- 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.
Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.